DRG Diagnostics, BIT Analytical Instruments to launch new product

BIT Analytical Instruments GmbH (www.BIT-Companies.com), a complete contract product development, manufacturing services and after-sales service provider to medical and industrial instrument OEM clients, partnered with DRG Diagnostics to launch a revolutionary new product - the DRG:HYBRID XL Analyzer, a fully-automated and integrated random-access analyzer for immunoassays and clinical chemistry. This innovative and unique technology allows, for the first time, the simultaneous measurement of immunoassays and clinical chemistry parameters including turbidimetric tests in one work routine. Following the system requirements defined by DRG, BIT Companies provided the hybrid technology concept and developed the core product idea and industrial design through to engineering, prototype, validation and final production.

The launch event took place on Wednesday, August 22 in Bad Soden, Germany at the facility of BIT's parent company, Messer GmbH. In attendance were key corporate executives and project team members from BIT, Messer and DRG. "The DRG:HYBRID XL Analyzer represents a successful partnership in design and development," said Mr. Balger, CEO of BIT. The marketplace is waiting in anticipation for this machine - a model of ingenuity and efficiency with two instruments combined within one compact unit. We are fortunate to have been a partner in this development process, as it has been very valuable and given us great insight in the future design of instruments using our BIT platform modules."

"Our expectations are very high for the success of the DRG: HYBRID XL Analyzer," said Mr. Sänger, Managing Director for DRG. "We anticipate that DRG's Hybrid will replace many existing instruments over the coming year."